NextGen Healthcare Launches Collaborative Care Solution for Data-Driven Population Health Management

HORSHAM, Pa.--(BUSINESS WIRE)-- NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. (NASDAQ: QSII) and a leading provider of healthcare information systems, services, and connectivity solutions, today announced the launch of NextGen® Care, a new population health and care management solution designed to streamline the care team’s workflow, more effectively manage patient populations, drive better outcomes and decrease cost of care delivery mandated by evolving value-based payment models. The solution provides risk scoring to deliver actionable insights and point-of-care alerts, enabling care team members to easily identify gaps in patient care, automate outreach and manage specialist referrals; especially for those with chronic conditions.

NextGen Care, a complete, collaborative care solution, is built on the Company’s core ambulatory solution suite and fully integrates with the NextGen® ambulatory product suite as well as patient engagement and measurement tools including NextGen® Patient Portal and NextGen®Dashboard. NextGen Care combines automated patient outreach with an embedded care management suite affording care managers the ability to execute multiple tasks for multiple patients―all from a single screen. With population health management at the heart of collaborative care, NextGen Care enables any practice to identify high-risk patients, as well as those requiring preventive care, and deliver proactive targeted outreach anytime, anywhere.

In addition to managing care from a single platform, the interoperability achieved through NextGen® Share, a national health information service provider (HISP), further facilitates seamless data sharing to ensure care team members - internal and external - can access patients’ longitudinal health records. NextGen Care has been distinctively designed to arm providers with all the tools needed to deliver cohesive, value-based care to high-risk populations. Providers and clinicians can use NextGen Care to improve clinical and financial outcomes and meet the ever-increasing demand for quality reporting while significantly reducing the cost of delivering, monitoring and measuring care.

NextGen Care is designed for providers using the NextGen® ambulatory product suite. It complements Mirth® Care Enterprise, the recentlylaunched vendor-neutral platform unveiled by QSI subsidiary Mirth, LLC.

“We’ve developed a cohesive delivery system that facilitates easy access, sharing and analysis of health data and brings care team members the right information, the way they want it, when they need it,” said Michael Lovett, executive vice president and general manager for NextGen Healthcare. “With the onslaught of changes in healthcare, regulatory mandates, and the demand for high-quality reporting, care teams need interoperable solutions like NextGen Care to succeed amid the nation’s new value-based landscape. NextGen Care equips our clients with the population health management solutions necessary to drive strategies and interventions, allowing them to improve the health of the individuals within the patient populations they manage in the most cost effective manner.”

About NextGen Healthcare

NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc., provides integrated clinical, connectivity and financial solutions, including revenue cycle management services for ambulatory, inpatient and dental provider organizations. For more information, visit www.nextgen.com and www.qsii.com. Follow us on TwitterFacebookLinkedIn and YouTube.

About Quality Systems Inc

Irvine, Calif.-based Quality Systems, Inc. and its NextGen Healthcare subsidiary develop and market computer-based practice management, electronic health records and revenue cycle management applications as well as connectivity products and services for medical and dental group practices and small hospitals. Visit www.qsii.com and www.nextgen.com for additional information.

Certain statements in this news release are forward-looking statements within the meaning of the federal securities laws, including but not limited to statements related to the Company’s future products and offerings, statements made by Michael Lovett about the Company’s future products and offerings, and developments and trends in the healthcare industry. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Factors that could cause the anticipated results to differ from those described in the forward-looking statements include the possibility that products will not achieve or sustain market acceptance; the impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in our software; changing economic, political or regulatory influences in the healthcare industry; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; and general economic conditions. Additional risks and uncertainties are set forth in the Company’s public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
© 2015 Quality Systems, Inc., Irvine, CA 92612
® marks owned by Quality Systems, Inc.
All other non-QSI Marks are the property of their respective owners

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.